Multiple Myeloma Face-Off: Ken Shain, MD, PhD, and Sikander Ailawadhi, MD, on ASH 2022

Ken Shain, MD, PhD, discussed some of the research in multiple myeloma that was featured in a recent FaceOff program, and how these recent advances may change the standard of care.

Ken Shain, MD, PhD, spoke about the dramatic impact of novel immunotherapies in the multiple myeloma treatment landscape, as well as other updates from the 2022 ASH Annual Meeting and Exposition.

Ken Shain, MD, PhD, provides an overview of developments on the horizon in multiple myeloma.

Ken Shain, MD, PhD, pinpoints the critical, lingering gaps in patient access to cellular immunotherapies in multiple myeloma.

Sikander Ailawadhi, MD, discussed the safety and efficacy of talquetamab in heavily pretreated patients with relapsed/refractory multiple myeloma following a readout of the phase 1/2 MonumenTAL-1 trial.

Experts from the Mayo Clinic and Moffitt Cancer Center go head-to-head to discuss recent data in multiple myeloma and updates from recent meetings.